Additional file 1: of Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Susceptibility inputs - Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) dataset. (DOCX 25 kb